Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Proliferative Retinopathy Clear all
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684
View directory record Official record
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
OTT166, Vehicle control
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
67
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

NCT00606138
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Withdrawn Phase 3 Interventional

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

NCT01589718
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen, Sham
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 21, 2026, 11:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Against Recurrent Retinal Detachment

NCT02192970
View directory record Official record
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

NCT00395707
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lucentis, Ranibizumab, Ranibizumab (Lucentis)
Drug
Lead sponsor
The National Retina Institute
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chevy Chase, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Jul 21, 2026, 11:19 AM EDT
Active, not recruiting Phase 3 Interventional

Fenofibrate for Prevention of DR Worsening

NCT04661358
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 80 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
66
States / cities
Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

NCT00445003
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
Drug · Behavioral · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
56
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed No phase listed Observational

Retrospective Review of Proliferative Diabetic Retinopathy Patients

NCT03609996
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Panretinal Photocoagulation, Lucentis
Device · Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

NCT02976012
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Aflibercept, Endolaserless Vitrectomy
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

NCT00470977
View directory record Official record
Conditions
Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
ranibizumab injection (0.5 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

NCT05695417
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
OTX-TKI, Sham
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography

NCT01790945
View directory record Official record
Conditions
Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Hilo, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Early Phase 1 Interventional

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT03727776
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

NCT03197870
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
AKB-9778, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Early Phase 1 Interventional

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

NCT03571100
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1 Interventional

Propranolol for Diabetic Retinopathy

NCT01535495
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Propranolol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

NCT05066230
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
KSI-301, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Jul 21, 2026, 11:19 AM EDT
Enrolling by invitation Phase 4 Interventional

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

NCT06191094
View directory record Official record
Conditions
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions
Faricimab Injection, sham treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Results available

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

NCT01069341
View directory record Official record
Conditions
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Bhagat, Neelakshi, M.D., M.P.H.
Individual
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Phase 2 Interventional

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT05393284
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions
OPL-0401 Dose 1, Placebo
Drug
Lead sponsor
Valo Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Mountain View, California • Riverside, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Not applicable Interventional

The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

NCT01880372
View directory record Official record
Conditions
Moderate Non-proliferative Diabetic Retinopathy
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
Ferris State University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Big Rapids, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 21, 2026, 11:19 AM EDT